241
1995; 42:907-912.
34.
Yuluğtekin Z. Kronik hepatit tedavisinde ilaca bağlı yan etkilerin yönetimi. Viral
Hepatit Kitabı 2009. 227-231 Ed: Tabak F, Balık İ. 1. baskı. İstanbul.
35.
Pegasys (peginterferon alfa-2a) package insert, Hoffmann-La Roche Inc, Nutley,
NJ, 2011.
36.
Vial T, Choquet-Kastylevsky G, Liautard C, Descotes J. Endocrine and neurological
adverse effects of the therapeutic interferons. Toxicology 2000; 142:161-172.
37.
Oguz S, Yurdagül E, Aydin H, Ünal M. Interferon alfa kullanımına baglı psikotik
bozukluk: Olgu sunumu. Klinik Psikiyatri 2003;6:170-3.
38.
HO SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of
psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a
veteran population. Am J Gastroenterol 2001; 96:157-164.
39.
Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse
effects of interferon-alpha: recognition and management. CNS Drugs 2005;
19:105-123.
40.
Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C,
interferon alfa, and depression. Hepatology 2000; 31:1207-1211.
41.
Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus
on IFN alpha-induced depression. Gastroenterol Clin North Am 2004; 33:S35-S50.
42.
Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of
interferon-alfa-induced depressive disorder. Med J Aust 2000; 173:359-361.
43.
Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid function and changes
in ultrasound morphology during antiviral therapy with pegylated interferon and
ribavirin in patients with chronic hepatitis C. J Viral Hepat 2009; 16:168-177.
44.
Mehta N, Murthy UK, Kaul V, Alpert S, Abruzzese G, Teitelbaum C. Outcome of
retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.
Dig Dis Sci 2010; 55:452-457.
45.
Kawano T, Shigehira M, Uto H ve ark. Retinal complications during interferon
therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91:309-313.
46.
Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing
pneumonia. Chest 1994; 106:612-613.
47.
Ramos-Casals M, Mana J, Nardi N ve ark. Sarcoidosis in patients with chronic
hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005; 84:69-
80.
48.
Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)
interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
Dig Dis Sci 2010; 55:579-585.
49.
Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor
for development of thyroid disease during interferon-alpha therapy for chronic
hepatitis C. Am J Gastroenterol 1994; 89:399-403.
50.
Moncoucy X, Leymarie F, Delemer B ve ark. Risk factors and long-term course of
thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis
C. Gastroenterol Clin Biol 2005; 29:339-345.
51.
Fontaine H, POL S. Side effects of interferon-alpha in treating hepatitis C virus
infection. Transplant Proc 2001; 33:2327-2329.
52.
Dumas V, Thieulent N, Souillet AL, Jullien D, Faure M, Claudy A. Recurrent
erythema multiforme and chronic hepatitis C: efficacy of interferon alpha. Br J
Dermatol 2000; 142:1248-1249.
53.
Hadziyannis SJ. Skin diseases associated with hepatitis C virus infection. J Eur
İlaç Yan Etkilerinin Yönetimi
